KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Change in Intangibles (2018 - 2025)

Historic Change in Intangibles for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to -$1.2 billion.

  • Takeda Pharmaceutical's Change in Intangibles fell 142145.67% to -$1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year decrease of 11467.3%. This contributed to the annual value of -$965.3 million for FY2025, which is 5440.2% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Change in Intangibles stood at -$1.2 billion, which was down 142145.67% from -$86.4 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Change in Intangibles ranged from a high of -$75.1 million in Q3 2024 and a low of -$3.1 billion during Q1 2023
  • Its 5-year average for Change in Intangibles is -$478.7 million, with a median of -$187.8 million in 2021.
  • Per our database at Business Quant, Takeda Pharmaceutical's Change in Intangibles plummeted by 210838.23% in 2023 and then soared by 9567.39% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Change in Intangibles stood at -$187.9 million in 2021, then skyrocketed by 35.36% to -$121.5 million in 2022, then plummeted by 67.35% to -$203.3 million in 2023, then soared by 62.58% to -$76.1 million in 2024, then plummeted by 1421.46% to -$1.2 billion in 2025.
  • Its last three reported values are -$1.2 billion in Q4 2025, -$86.4 million for Q3 2025, and -$187.7 million during Q2 2025.